Bioventus (BVS)
Makes orthopedic treatments for knee pain, surgical bone repair, and fracture healing.
Something off on this page? Send us feedback.
Sells hyaluronic-acid knee injections, surgical biologics and ultrasonic tools, and EXOGEN bone stimulation through U.S. and international segments. Revenue is concentrated in the United States, and the business depends on physician adoption, reimbursement rules for viscosupplementation, and FDA/CMS treatment of bone-growth stimulators.
Centers on musculoskeletal products sold through Pain Treatments, Surgical Solutions, and Restorative Therapies. Pain Treatments includes DUROLANE, GELSYN-3, and SUPARTZ FX knee osteoarthritis injections, while Surgical Solutions covers bone-graft products and neXus ultrasonic surgical tools, and Restorative Therapies is now built around EXOGEN bone stimulation.
Sales run through U.S. and International segments and are concentrated in the United States. The portfolio was narrowed after CartiHeal obligations, Wound Business divestiture, and the Advanced Rehabilitation sale, leaving core orthopedic pain, surgery, and bone-healing franchises.
Execution depends on clinical adoption by orthopedic and pain-care providers, reimbursement for viscosupplementation products, and regulatory treatment of bone-growth stimulators such as EXOGEN.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $15 | Target: $19 |
| Aug 6, 2026 | Craig-Hallum | Reiterate | Rating: —Target: $15 | Target: $18 |
| Aug 6, 2026 | Barrington | Target | Target: $13 | Target: $18 |
| Jun 16, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $12 | Target: $15 |
| Feb 9, 2026 | Barrington | Target | Target: — | Target: $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 27, 2026Cash & short-term investments $29.5M · Total debt $263.7M · Total assets $673.3M · Shareholders' equity $228.3M
- Revenue
- $153.2M
- Operating income
- $19.1M
- Net income
- $33.4M
No dividends on record.
Unavailable right now.
- Anika Therapeutics
HA knee OA injections and regenerative orthopedics peer
- Sanofi (ADR)
Synvisc franchise rival in knee OA viscosupplementation
- Orthofix Medical
Bone stimulation and orthobiologics rival
- Zimmer Biomet
HA, PRP, and bone-graft overlap in orthopedics
- Medtronic
Scale spine-biologics rival in bone graft substitutes
- Integra LifeSciences
CUSA ultrasonic aspirator rival for neXus
- Stryker
Ultrasonic aspirator and bone-grafting rival
- Boston Scientific
Peripheral nerve stimulation rival through Nalu
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bioventus | $13.58 | +2.04% | $901.7M | 17.3 | 17.1 | 1.5 | +3.8% |
| Anika Therapeutics | $21.05 | +1.69% | $277.0M | — | 23.7 | 2.3 | +15.6% |
| Sanofi (ADR) | $42.46 | −0.09% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Orthofix Medical | $9.10 | +1.68% | $361.8M | — | — | 0.4 | +5.1% |
| Zimmer Biomet | $94.11 | −0.22% | $18.25B | 22.9 | 10.7 | 2.1 | +4.8% |
| Medtronic | $91.28 | −0.51% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Integra LifeSciences | $16.00 | +2.64% | $1.21B | — | 6.3 | 0.7 | +0.8% |
| Stryker | $276.27 | +0.76% | $105.11B | 28.4 | 17.3 | 4.1 | +9.4% |
| Boston Scientific | $44.72 | +2.29% | $64.98B | 17.8 | 13.6 | 3.1 | +7.5% |
| Median | 22.9 | 14.4 | 2.2 | +8.5% |